Cevec Signs Global Licensing Agreement with Life Technologies
Cologne/Carlsbad – Protein expression provider CEVEC Pharmaceuticals has signed a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to globally offer researchers optimized expression kits based on CEVEC’s proprietary novel human protein expression system derived from the company’s CAP-T amniocytes. Life Technologies will pay CEVEC a signing fee plus milestones and royalties on sales of future products, but further details of the agreement were not disclosed. CEVEC’s transient CAP-T protein production technology is based on a human immortalized cell line for stable protein production derived from amniocytes. The proprietary cells are optimized to grow in serum-free suspension cultures, and show human-like post-translational modifications, including authentic human glycosylation patterns.